No recent analyst price targets found for AUC.
Latest News for AUC
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited
UP Fintech: Q1 Revenue and Client Assets Grow Steadily, Total Revenue Up 26.3% YoY
UP Fintech: Q1 Revenue and Client Assets Grow Steadily, Total Revenue Up 26.3% YoY PR Newswire NEW YORK, June 2,
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for AUC.
Senate Trading
No Senate trades found for AUC.
U.S. House Trading
No House trades found for AUC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.